The effect of food on and the intra-subject variability of the pharmacokinetics of ZD6474, a novel antiangiogenic agent, in healthy subjects
Robert P. Smith(MaineHealth), Robert Oliver(AstraZeneca (United Kingdom)), D. Sandall(AstraZeneca (United Kingdom)), S. Kennedy(AstraZeneca (United Kingdom)), Jane Robertson(Cancer Research UK)
Cited by 5
Related Papers
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2007|303
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
|Gynecologic Oncology|2015|301
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
|British Journal of Cancer|2018|233